July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
To read this article for CME, click here. November 20, 2008 — Testing for KRAS gene mutations has been added to the updated National Comprehensive Cancer Network (NCCN) clinical-practice guidelines ...
Merck & Co. is expanding its partnership with the mRNA company Moderna Therapeutics. Under the deal, Merck will make a $125 million investment into Moderna. In addition, the big drug company will ...
Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Supported in part by the United States Department of Veterans Affairs, Veterans ...
PLEASANTON, Calif., May 11, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the cobas® KRAS Mutation Test for ...
More than 90% of pancreatic ductal adenocarcinoma (PDAC) cases harbor activating mutations in the KRAS (Kristen’s rat sarcoma viral oncogene homolog (KRAS) gene 1. KRAS mutant proteins exert their ...
Q: Should I be tested for the KRAS mutation before beginning colorectal cancer treatment? Recent research confirmed that the mutation status of the KRAS gene in colon cancer patients can determine if ...
New mutation-testing technology has potential to guide targeted lung and colorectal cancer therapies
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The ...
KRAS is one of the leading mutations reported in colon cancer. However, there are few studies on the application of KRAS related signature in predicting prognosis and drug sensitivity of colon cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results